The proxy fight outcome is binary: a DOMA win could trigger a sale process or cost cuts, while a Pacira win maintains current strategy. The cross-filing amplifier suggests this activist context increases expected stock movement. Monitor vote tallies and any further 13D filings from DOMA. The June 9 meeting date is the key catalyst.
PCRX drugs
PCRX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK AT ENTRY AT T+60- T+0 · May 20 $23.00entry
- T+1 · 6mo ago +2.09%α +1.89% · $23.48
- T+5 · 6mo ago +2.96%α +1.15% · $23.68
- T+20 · 5mo ago −2.91%α −3.65% · $22.33
- T+60 · 3mo ago 0.00%α −5.00% · $23.00
Price Chart
How similar events traded
Executive Summary
Pacira BioSciences issued a press release urging stockholders to vote for its board nominees at the June 9 annual meeting, countering activist DOMA Perpetual Capital Management. The company highlighted record 2025 revenue of $726.4M, 79.4% GAAP gross margins, and a $200M buyback return since April 2025, while criticizing DOMA's plan to cut costs, halt pipeline development, and pursue a sale. This is an escalating proxy fight with material implications for strategic direction.
Key Financial Metrics
Key Facts
- Pacira achieved record total revenue of $726.4M in 2025 with GAAP gross margins of 79.4% and non-GAAP gross margins of 81.2%.
- Q1 2026 revenue: EXPAREL $143.3M (+5% YoY), ZILRETTA $26.8M (+15% YoY), iovera° $6.2M (+21% YoY).
- Company has returned $200M to stockholders since April 2025 under a $300M share repurchase program.
- Pacira reached a volume-limited settlement in EXPAREL patent litigation securing exclusivity through 2030.
- Activist DOMA Perpetual Capital Management seeks to replace three directors, cut costs, discontinue pipeline, replace CEO, and initiate a sale process.
- Annual meeting scheduled for June 9, 2026; record date April 22, 2026.
- Pacira's board would be 89% independent with average tenure of ~4.6 years after the meeting.
- Cross-filing context: press-8k-context + press-activist-context is an amplifier (PMI=2.28, q=0.000, n=3144).
Financial Impact
Record revenue of $726.4M in 2025; Q1 2026 revenue growth across all three products (5-21% YoY); $200M returned via buybacks; $300M buyback program authorized.
Risk Factors
- Activist victory could lead to a fire sale at potentially depressed valuation.
- DOMA's proposed cost cuts may harm revenue growth and pipeline prospects.
- Patent litigation settlement is volume-limited, leaving some uncertainty on exclusivity beyond 2030.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3298294 |
Track record
29 reports on PCRX
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.26% at T+60 after the Aug 6, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 6/10 Entry $36.46 Now $36.48 −0.05% settles Dec 14
- Nov 12, 20264d ago SC TO-T/A Mixed 7/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 12, 20264d ago SC 14D-9/A Neutral 3/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $36.43 Now $36.48 +0.14% settles Dec 7
- Nov 3, 202613d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 30, 202617d ago SC 14D-9 Bullish 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 30, 202617d ago SC TO-T Mixed 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 13, 20264w ago SC 13D/A Bearish 7/10 Entry $36.40 to $36.46 Now $36.48 −0.22% ▼ −0.16% −1.44% vs SPY
- Oct 8, 20265w ago SC TO-C Bullish 7/10 Entry $36.31 to $36.43 Now $36.48 +0.47% ▲ +0.33% +5.89% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers